Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease

被引:2
作者
Ting, Peng-sheng [1 ]
Lin, Wei-Ting [2 ]
Huang, Chiung-Kuei [3 ]
Lin, Hui-Yi [4 ]
Tseng, Tung-Sung [4 ]
Chen, Po-Hung [5 ]
机构
[1] Tulane Univ, Sch Med, Div Gastroenterol & Hepatol, 1430 Tulane Ave, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Publ Hlth & Trop Med, Social Behav & Populat Sci, New Orleans, LA USA
[3] Tulane Univ, Sch Med, Dept Pathol, New Orleans, LA 70112 USA
[4] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, New Orleans, LA USA
[5] Johns Hopkins Univ, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD USA
来源
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH | 2024年 / 48卷 / 01期
关键词
liver fibrosis; metabolic dysfunction-associated steatotic liver disease; nonheavy alcohol use; PREVALENCE;
D O I
10.1111/acer.15220
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol consumption have both increased in recent years, and there is debate as to whether nonheavy alcohol use is safe in MASLD. We analyzed the association between different nonheavy alcohol use patterns and at-risk liver fibrosis among individuals with MASLD.Methods: We conducted a cross-sectional study of 1072 eligible National Health and Nutrition Examination Survey participants with MASLD who reported nonheavy alcohol consumption. We used vibration-controlled transient elastography to define the primary outcome of at-risk liver fibrosis as >8.2 kPa (stage F2-F4). Multivariable logistic regression models were used to determine the association of different alcohol consumption patterns (average drinks/day, drinking days/week, weekly alcohol intake, type of alcoholic beverage) and at-risk hepatic fibrosis, controlling for demographic/socioeconomic, lifestyle/dietary, and metabolic risk factors.Results: Exclusive liquor or cocktail drinkers had a 5.02-fold odds of at-risk fibrosis (95% CI: 1.15-21.95) compared with non-drinkers when controlling for potential confounders. While consuming an average of 2 drinks/day, >= 3 drinking days/week, or 1-3 drinks/week appeared to have a lower association with at-risk fibrosis when controlling for demographic/socioeconomic risk factors, the association was not present after controlling for lifestyle/dietary and metabolic risk factors.Conclusions: There is an association between exclusive liquor/cocktail consumption and at-risk liver fibrosis in patients with MASLD who report nonheavy alcohol consumption.
引用
收藏
页码:88 / 97
页数:10
相关论文
共 50 条
  • [21] Iron, Oxidative Stress, and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Gensluckner, Sophie
    Wernly, Bernhard
    Datz, Christian
    Aigner, Elmar
    ANTIOXIDANTS, 2024, 13 (02)
  • [22] Influence of dispersion slope on the diagnosis of liver fibrosis by the shear wave in metabolic dysfunction-associated steatotic liver disease
    Ueda, Naoyuki
    Mokuda, Sho
    Kawaoka, Tomokazu
    Uchikawa, Shinsuke
    Amioka, Kei
    Tsuge, Masataka
    Asada, Kana
    Okada, Yuri
    Kobayashi, Yui
    Ishikawa, Mai
    Arase, Takashi
    Arihiro, Koji
    Oka, Shiro
    HEPATOLOGY RESEARCH, 2024, 54 (12) : 1139 - 1147
  • [23] Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease
    Righetti, Riccardo
    Cinque, Felice
    Volpe, Maria Teresa
    Sebastiani, Giada
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (07) : 303 - 313
  • [24] Food insecurity is a risk factor for metabolic dysfunction-associated steatotic liver disease in Latinx children
    Maxwell, Sarah L.
    Price, Jennifer C.
    Perito, Emily R.
    Rosenthal, Philip
    Wojcicki, Janet M.
    PEDIATRIC OBESITY, 2024, 19 (06):
  • [25] Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease and Cardiometabolic Risk Factor in US Adolescents
    Zheng, Xiaoyan
    Zhao, Dongying
    Wang, Liwei
    Wang, Yiwen
    Chen, Yan
    Zhang, Yongjun
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, : e1458 - e1465
  • [26] The association between estimated glucose disposal rate and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in US adults
    Liu, Wanqian
    Li, Xiaozhong
    Chen, Ling
    Luo, Xiao
    BMC ENDOCRINE DISORDERS, 2025, 25 (01)
  • [27] Association of liver fibrosis progression with non-liver-related mortality in metabolic dysfunction-associated steatotic liver disease
    Tada, Toshifumi
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Koshiyama, Yuichi
    Akita, Tomoyuki
    Kodama, Yuzo
    Tanaka, Junko
    HEPATOLOGY RESEARCH, 2025,
  • [28] Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease
    Sohn, Won
    Kwon, Heon-Ju
    Chang, Yoosoo
    Ryu, Seungho
    Cho, Yong Kyun
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1135 - E1148
  • [29] The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
    Paklar, Natasa
    Mijic, Maja
    Filipec-Kanizaj, Tajana
    BIOMEDICINES, 2023, 11 (11)
  • [30] Non-invasive testing in metabolic dysfunction-associated steatotic liver disease
    Dawod, Sanad
    Brown, Kimberly
    FRONTIERS IN MEDICINE, 2024, 11